Brivaracetam

Generic Name: Brivaracetam

Brand Names: Briviact, Briviact (in Italy: Nubriveo)

Drug Type: Small Molecule

Chemical Formula: C_₁₁H_₂₀N_₂O_₂

CAS Number: 357336-20-0

Unique Ingredient Identifier: U863JGG2IA

Background: Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 .

Indication: Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.

Associated Conditions: Partial-Onset Seizures

Associated Therapies: -

Clinical Trials

Epileptic Hippocampus in Alzheimer's Disease

Phase 1

Not yet recruiting

Conditions: Mild Cognitive Impairment
Alzheimer Disease

Interventions: Drug: Brivaracetam

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 25

Registration Number: NCT05899764

Locations: 🇺🇸
Mary S. Easton Center for Alzheimer's Research and Care, Los Angeles, California, United States

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Phase 3

Active, not recruiting

Conditions: Spinal Cord Injuries
Neuropathic Pain

Interventions: Drug: Placebo
Drug: brivaracetam

First Posted Date: 2022-12-07

Last Posted Date: 2024-10-17

Lead Sponsor: University of Minnesota

Target Recruit Count: 40

Registration Number: NCT05639946

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: brivaracetam

First Posted Date: 2022-04-07

Last Posted Date: 2024-01-05

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 24

Registration Number: NCT05315947

Locations: 🇯🇵
EP0110 1, Sumida-ku, Japan

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

Early Phase 1

Active, not recruiting

Conditions: Brain Tumor

Interventions: Drug: Brivaracetam

First Posted Date: 2021-09-01

Last Posted Date: 2024-08-09

Lead Sponsor: University of Rochester

Target Recruit Count: 30

Registration Number: NCT05029960

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: brivaracetam

First Posted Date: 2021-05-12

Last Posted Date: 2023-03-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 12

Registration Number: NCT04882540

Locations: 🇨🇳
Ep0101 101, Shanghai, Shanghai, China

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Phase 3

Active, not recruiting

Conditions: Epilepsy

Interventions: Drug: Brivaracetam

First Posted Date: 2021-01-20

Last Posted Date: 2024-10-04

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 70

Registration Number: NCT04715646

Locations: 🇮🇹
Ep0156 230, Roma, Italy
🇭🇺
Ep0156 210, Budapest, Hungary
🇯🇵
Ep0156 809, Shimotsuke, Japan

and more 23 locations

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Recruiting

Conditions: Juvenile Absence Epilepsy
Childhood Absence Epilepsy

Interventions: Drug: Brivaracetam
Other: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2024-12-13

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 160

Registration Number: NCT04666610

Locations: 🇺🇸
N01269 103, Loxahatchee Groves, Florida, United States
🇺🇸
N01269 115, Birmingham, Alabama, United States
🇺🇸
N01269 118, Long Beach, California, United States

and more 50 locations

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

Phase 1

Active, not recruiting

Conditions: Spinal Cord Injuries

Interventions: Drug: Brivaracetam
Other: Placebo

First Posted Date: 2020-05-07

Last Posted Date: 2024-05-03

Lead Sponsor: University of Minnesota

Target Recruit Count: 24

Registration Number: NCT04379011

Locations: 🇺🇸
University of Minnesota School of Medicine, Minneapolis, Minnesota, United States
🇺🇸
Swedish Hospital, Englewood, Colorado, United States

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Phase 1

Completed

Conditions: Epilepsy

Interventions: Drug: Padsevonil
Drug: Levetiracetam
Drug: Oxcarbazepine
Drug: Lamotrigine
Drug: Brivaracetam

First Posted Date: 2018-10-03

Last Posted Date: 2020-06-04

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 31

Registration Number: NCT03695094

Locations: 🇳🇱
Up0070 401, Leiden, Netherlands
🇧🇬
Up0070 101, Sofia, Bulgaria

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Phase 3

Completed

Conditions: Partial Seizures With or Without Secondary Generalization
Epilepsy

Interventions: Drug: Brivaracetam

First Posted Date: 2018-09-26

Last Posted Date: 2021-04-13

Lead Sponsor: UCB Biopharma S.P.R.L.

Target Recruit Count: 10

Registration Number: NCT03685630

Locations: 🇯🇵
Ep0118 121, Itami, Japan
🇯🇵
Ep0118 126, Bunkyo, Japan
🇯🇵
Ep0118 116, Asaka, Japan

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy